Peregrine Pharma New (PPHM) 0.42 $PPHM Peregrine

New Post Public Reply Private Reply Replies (0) Message Board

Apr 1, 2016 at 3:44 AM

Peregrine Pharma New (PPHM) 0.42 $PPHM

Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments
GlobeNewswire - Wed Mar 09, 7:22AM CST
--Company Focused on Advancing Its Bavituximab Immuno-Oncology Program Through Its Pharmaceutical, Academic and Clinical Collaborations--
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

Peregrine reports 3Q loss
Automated Insights - Wed Mar 09, 7:13AM CST
TUSTIN, Calif. (AP) _ Peregrine Pharmaceuticals Inc. (PPHM) on Wednesday reported a loss of $16.8 million in its fiscal third quarter.
PPHM: 0.42 (+0.02)

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
GlobeNewswire - Mon Mar 07, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (Nasdaq

PHM) (Nasdaq

PHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"

.
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

Peregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing Facility
GlobeNewswire - Mon Mar 07, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that its new state-of-the-art commercial biomanufacturing suite in Tustin, California, has been formally commissioned. As part of the commissioning process, all relevant regulatory agencies have been notified and cGMP production is currently underway. The new Peregrine facility, which is being operated by Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine, will more than double the company's prior manufacturing capacity, supporting up to an additional $40 million in revenue each year.
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016
GlobeNewswire - Thu Mar 03, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the third quarter of fiscal year 2016 ended January 31, 2016 on March 9, 2016 prior to market open and will host a conference call and webcast at 8:30 AM Pacific Time (11:30 AM Eastern Time). Peregrine's senior management will discuss financial results for the third quarter and review the recent progress of its clinical development programs.
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

OncBioMune Patents a New Promising Approach to Chemotherapy
ACCESSWIRE - Thu Jan 28, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / Chemotherapy compounds like paclitaxel and docetaxel have been used for years to treat cancer, but the caveat is that they indiscriminately kill both cancerous and normal cells. In order to solve this problem, researchers have tried a number of different approaches. The most common approach has been conjugating anti-cancer agents to antibodies or functional fragments, but even then, there are significant numbers of normal cells affected.
SGEN: 35.09 (+1.45), IMGN: 8.52 (+0.26), PPHM: 0.42 (+0.02), SRNE: 5.38 (+0.15), CELG: 100.09 (+1.29)

Peregrine Pharma (PPHM): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 7:43AM CST
Peregrine Pharma is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
PPHM: 0.42 (+0.02)

Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences
GlobeNewswire - Wed Jan 20, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that members of the company's scientific team will deliver podium presentations focused on the role of combination immunotherapies in the treatment of cancer at two upcoming immunotherapy conferences. Jeff T. Hutchins, Ph.D., Peregrine's vice president, preclinical research, will speak at Immunotherapy World 2016, being held January 25-27, 2016 in Washington, D.C. Additionally, Bruce Freimark, Ph.D., research director, preclinical oncology at Peregrine, will present at GTCBio's 8th Immunotherapeutics & Immunomonitoring Conference, being held January 25-26, 2016 in San Diego, CA.
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers
GlobeNewswire - Mon Jan 11, 7:05AM CST
-- Phase II Study in NSCLC in Collaboration with AstraZeneca Evaluating Bavituximab Plus Durvalumab to Expand Lung Cancer Program in Q1 2016 --
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

Peregrine (PPHM) Inks Research Partnership for Bavituximab
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:00PM CST
Peregrine (PPHM) is collaborating with the National Comprehensive Cancer Network to evaluate bavituximab for the treatment of a range of tumors.
AZN: 28.16 (-0.16), HZNP: 16.57 (+0.56), PPHM: 0.42 (+0.02), SNY: 40.16 (-0.53)

Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
GlobeNewswire - Wed Jan 06, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network(R) (NCCN(R)) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors. NCCN, a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate community hospitals through a $2 million research grant to NCCN's Oncology Research Program (ORP). NCCN will be responsible for oversight and monitoring of the clinical studies through the research grant.
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

Surging Earnings Estimates Signal Good News for Peregrine Pharmaceuticals (PPHM)
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 7:46AM CST
Peregrine Pharmaceuticals has decent short-term momentum and is also seeing solid activity on the earnings estimate revision front as well.
PPHM: 0.42 (+0.02)

The Life Sciences Report Announces 19 Companies for the 2016 Small-Cap Biotech Watchlist
Marketwired - Tue Dec 22, 8:01AM CST
In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.
CRMD: 2.65 (+0.22), PIRS: 1.90 (unch), AST: 4.70 (+0.01), PPHM: 0.42 (+0.02)

Why You Shouldn't Bet Against Peregrine Pharmaceuticals (PPHM) Stock
Zacks Equity Research - Zacks Investment Research - Tue Dec 22, 7:39AM CST
Peregrine Pharmaceuticals (PPHM) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
PPHM: 0.42 (+0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

USPS Rolls Out Christmas Cookie Stamps Nationwide

USPS Delivers Nostalgia with Cookie-Themed Stamps Let's talk stamps, folks. The U.S. Postal Service has rolled out its newest Christmas Cookies Forever stamps, bringing a dash of sugary nostalgia to mailboxes nationwide. The release was celebrated at the Smithsonian National Postal Museum, spotlighting a tradition as sweet as the sugar cookies themselves. These aren't...

Insta360 Expands with Times Square Flagship Store

Insta360 Times Square Opening Marks Bold Expansion I dropped by Times Square today, and what do I see? Insta360 planting its flag right in the heart of New York City. Now, this isn't your run-of-the-mill grand opening—it’s the first flagship store outside of Asia, and it screams of big ambitions. Nestled at 1515 Broadway, the store is smack in the middle of one of the...

Why Liver Nurture Taps into Health Sector Trends

Liver Wellness: A Sector on the Rise Remember when everyone was all about heart health and cholesterol levels? Seems like these days, folks have shifted their focus a bit south—right to the liver. It's no surprise, really. With our modern diet and lifestyle choices squeezing the life out of this hard-working organ, people are on the hunt for ways to give it the TLC it...

BarrelPick.com Launches for Bourbon Aficionados

Just when you think you've seen all the ways to enjoy bourbon, along comes BarrelPick.com with a tantalizing new proposition. They're throwing down the gauntlet for bourbon lovers everywhere by letting you buy an entire barrel, let it sit around for a bit, watch it mature, and then call the shots on when it finally sees the light of day in a bottle. Talk about skipping...

Qatar Foundation Spurs Sport-Driven Empowerment Moves

Here we go, diving into the serious talk of the moment: sports pushing boundaries to uplift society's underdogs. Envision yourself in the halls of Wilton Park, where the thinkers, the dreamers, and the doers convened in the name of change. Qatar Foundation ain't just sitting pretty; they're championing the cause to harness sport for impactful social threads across the...

2026 Lantern Festival Shines in Kunshan Amid Tensions

Lanterns Illuminate Cross-Strait Relations Under the shadow of geopolitical tensions, the 2026 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival kicked off with a splash on September 16. Held in Kunshan, Suzhou, this cultural festival offers a rare glimpse of cooperation and shared cultural celebration across the Taiwan Strait. Through lantern displays, art exhibitions,...

Flying Car Regulatory Sandbox Begins in UAE

Pioneering Flying Cars in the Desert In a move that seems right out of a science fiction screenplay, ARIDGE—the bigwig of flying cars from Asia—has taken a giant leap. They’ve cozied up with the UAE, locking arms to cook up the world's first regulatory sandbox for personal flying cars. Now, don’t laugh—sandbox isn't just for toddlers. It’s the playground where...

Shanghai's Arts Carnival Fuses Tech and Culture

Shanghai Heralds New Era in Arts with Carnival Coming in hot, Shanghai's ready to shake up the city's cultural scene with the 2026 International Audio-Visual Arts Carnival. It's happening in Jing'an District from September 24 to October 18, promising an experience that fuses travel, technology, and art. Just about anyone can catch a break from their daily grind and dive...

Xi Jinping Thought: A Bold Prospect for Future Governance

107 years in the game, and the Communist Party of China (CPC) isn't showing any signs of slowing. With their recent conference in Beijing focusing on Xi Jinping Thought on Party Building, it’s clear they’ve got their eyes on the future, not just resting on past laurels. This Xi Jinping Thought is about a thorough self-improvement plan for the Party, a clear strategy...

Med Spa Visits: Key Insights from Lindsey Smith

Moving Beyond the Fear Factor Stepping into a med spa for the first time can be nerve-wracking, especially if you're unsure of what to expect. Lindsey Smith, an expert from Flawless Med Spa in Bryant, Arkansas, knows just how critical it is to navigate this terrain with clarity. Her approach emphasizes building a foundation of trust and understanding from the get-go. Fear...